Leap Therapeutics has successfully completed a $58.88 million private placement to fund its digital asset finance strategy. The biotechnology company, listed on NASDAQ as LPTX, received financial backing from Winklevoss Capital, which will also offer strategic support. This funding marks a significant step for Leap as it ventures into the digital asset space, leveraging the expertise of Winklevoss Capital to build and execute its strategy.